Serum biomarker panels for the detection of pancreatic cancer Journal Article


Authors: Brand, R. E.; Nolen, B. M.; Zeh, H. J.; Allen, P. J.; Eloubeidi, M. A.; Goldberg, M.; Elton, E.; Arnoletti, J. P.; Christein, J. D.; Vickers, S. M.; Langmead, C. J.; Landsittel, D. P.; Whitcomb, D. C.; Grizzle, W. E.; Lokshin, A. E.
Article Title: Serum biomarker panels for the detection of pancreatic cancer
Abstract: Purpose: Serum-biomarker based screening for pancreatic cancer could greatly improve survival in appropriately targeted high-risk populations. Experimental Design: Eighty-three circulating proteins were analyzed in sera of patients diagnosed with pancreatic ductal adenocarcinoma (PDAC, n = 333), benign pancreatic conditions (n = 144), and healthy control individuals (n = 227). Samples from each group were split randomly into training and blinded validation sets prior to analysis. A Metropolis algorithm with Monte Carlo simulation (MMC) was used to identify discriminatory biomarker panels in the training set. Identified panels were evaluated in the validation set and in patients diagnosed with colon (n = 33), lung (n = 62), and breast (n = 108) cancers. Results: Several robust profiles of protein alterations were present in sera of PDAC patients compared to the Healthy and Benign groups. In the training set (n=160 PDAC, 74 Benign, 107 Healthy), the panel of CA 19-9, ICAM-1, and OPG discriminated PDAC patients from Healthy controls with a sensitivity/specificity (SN/SP) of 88/90%, while the panel of CA 19-9, CEA, and TIMP-1 discriminated PDAC patients from Benign subjects with an SN/SP of 76/90%. In an independent validation set (n=173 PDAC, 70 Benign, 120 Healthy), the panel of CA 19-9, ICAM-1 and OPG demonstrated an SN/SP of 78/94% while the panel of CA19-9, CEA, and TIMP-1 demonstrated an SN/SP of 71/89%. The CA19-9, ICAM-1, OPGpanel is selective for PDAC and does not recognize breast (SP = 100%), lung (SP = 97%), or colon (SP = 97%) cancer. Conclusions: The PDAC-specific biomarker panels identified in this investigation warrant additional clinical validation to determine their role in screening targeted high-risk populations. ©2010 AACR.
Keywords: adult; cancer survival; human tissue; aged; major clinical study; cancer patient; diagnostic accuracy; sensitivity and specificity; protein analysis; controlled clinical trial; breast cancer; randomized controlled trial; ca 19-9 antigen; carcinoembryonic antigen; cancer screening; lung cancer; tumor marker; blood sampling; colon cancer; pancreas tumor; pancreas adenocarcinoma; benign tumor; cancer tissue; intercellular adhesion molecule 1; osteoprotegerin; tissue inhibitor of metalloproteinase 1; single blind procedure; diagnostic test accuracy study
Journal Title: Clinical Cancer Research
Volume: 17
Issue: 4
ISSN: 1078-0432
Publisher: American Association for Cancer Research  
Date Published: 2011-02-15
Start Page: 805
End Page: 816
Language: English
DOI: 10.1158/1078-0432.ccr-10-0248
PROVIDER: scopus
PUBMED: 21325298
PMCID: PMC3075824
DOI/URL:
Notes: --- - "Cited By (since 1996): 1" - "Export Date: 23 June 2011" - "CODEN: CCREF" - "Source: Scopus"
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Peter Allen
    501 Allen